Peptides Are Everywhere. Businesses Are Cashing In.

Experimental peptides have emerged as a massive wellness trend, driven by social media influencers and the success of GLP-1 medications. While these amino acid chains promise benefits like muscle growth, skin rejuvenation, and injury recovery, they largely remain unregulated and experimental, posing significant health risks including potential links to cancerous cell growth. The FDA is currently reviewing whether to allow compounding pharmacies to produce these substances, a shift encouraged by Robert F. Kennedy Jr. and anticipated by major telehealth players like Hims and Hers and Noom. These companies are actively acquiring compounding facilities to capture a potential $2 billion market opportunity. Despite the lack of formal FDA approval or rigorous safety data, consumers increasingly bypass traditional medical channels to access these substances, highlighting a growing reliance on anecdotal evidence over established regulatory oversight in the pursuit of longevity and physical enhancement.